Latest from Yale Cancer Center

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses key immunotherapy findings in non–small cell lung cancer, presented at the 2018 ASCO Annual Meeting.
Roy S. Herbst, MD, PhD, professor of medicine, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses tumor mutational burden (TMB) as a biomarker in non–small cell lung cancer (NSCLC). 
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).
Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the bevacizumab (Avastin) biosimilar in lung cancer.
Anne Chiang, MD, PhD, discusses recent developments with immunotherapy and the overall outlook for the treatment landscape of small cell lung cancer.
Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma.
Mario Sznol, MD, professor of Medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the importance of clinical trials in renal cell carcinoma.
James B. Yu, MD, discusses techniques with radiation therapy, potential roadblocks, and the importance of genomic testing in treating patients with prostate cancer.
Publication Bottom Border
Border Publication
x